Biotech, Partnering, Pharma

Triphase and Celgene announce a pharma deal for bi-specific antibodies

Posted on 29 October 2014

Tags: , , ,

Triphase Accelerator announced a new strategic pharma deal with Celgene.

The new agreement provides Celgene with the option to acquire a novel bi-specific antibody that Triphase licensed from PharmAbcine.

The bi-specific antibody targets VEGFR-2/TIE 2 and is currently in preclinical studies.

Triphase received an upfront payment and will control product development and retain all commercial rights to the bi-specific antibody.

If Celgene exercises its option to acquire the antibody from Triphase, Celgene will become responsible for product development and retain commercial rights, and Triphase will be eligible to receive regulatory and sales milestone payments if Celgene exercises its option to acquire the antibody.

For further deal information visit Current Agreements (subscription required)

Related

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Report: Top 50 Big Biotech Partnering and M&A Deal Trends

Browse: Complete Current Partnering report catalog

View: Partnering Scorecard in CP Insight– view top life science partnering deals by value

View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making

View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply